Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib + Induction Chemo in R/R AML
NCT02665143Phase 2Completed
- Sponsor
- Yale University
- Start
- Jul 2016
- Primary completion
- Mar 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in acute myeloid leukemia (AML), sponsored by Yale University. Started Jul 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02665143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02665143.